Integrative analysis of deoxyribonuclease 1-like 3 as a potential biomarker in renal cell carcinoma

• Published in: Translational andrology and urology 2023-08, Vol.12 (8), p.1308-1320
• Main Authors: Ge, Minghuan, Zhu, Hengcheng, Song, Huajie, Schmeusser, Benjamin N., Ng, Keng Lim, Zeng, Yan, Liu, Ting, Yang, Kang
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2223-4683; 2223-4691; 2223-4691
• DOI: 10.21037/tau-23-355

BackgroundClear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma (RCC), is insensitive to radiotherapy and chemotherapy after surgery. Deoxyribonuclease 1-like 3 (DNASE1L3), an endonuclease that cleaves both membrane-encapsulated single- and double-stranded DNA, suppresses cell cycle progression, proliferation and metabolism in hepatocellular carcinoma cells. There is currently no established link between DNASE1L3 and RCC inhibition. We are gonging to explored the mechanism underlying the relationship between DNASEL1L3 and RCC. MethodsRNA sequencing data for RCC tissue and peritumoral tissue were downloaded from The Cancer Genome Atlas database and analyzed. The expression levels of DNASE1L3 in RCC and normal samples were verified using the Gene Expression Omnibus (GEO) database, Human Protein Atlas database and western blotting. The role and potential mechanism of DNASE1L3 were investigated by analysis of immune-related databases and wound healing, invasion, cell counting kit 8 and immunofluorescence assays. ResultsWe revealed that DNASE1L3 expression was downregulated in RCC group compared with control group [The Cancer Genome Atlas (TCGA): 7.98 vs. 10.87, P